AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29191916 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib 25 or 75 mg twice daily continuously
Number of subjects: 210
Study 29191954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular movement test
Number of subjects: 0
Study 29191961 — intervention group
Group type: EXPERIMENTAL
Intervention: FCRx
Number of subjects: 0
Study 29191961 — intervention group
Group type: COMPARATOR
Intervention: Standard Immunosuppression (SIS)
Number of subjects: 0
Study 29192743 — intervention group
Group type: EXPERIMENTAL
Intervention: High adrenomedullin levels
Number of subjects: 440
Study 29192743 — intervention group
Group type: COMPARATOR
Intervention: Low adrenomedullin levels
Number of subjects: 440
Study 29193118 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic red blood cell transfusion
Number of subjects: 0
Study 29193542 — intervention group
Group type: EXPERIMENTAL
Intervention: quantitative fibrous collagen parameters (q-FP)
Number of subjects: 301
Study 29193542 — intervention group
Group type: COMPARATOR
Intervention: Ishak fibrosis staging
Number of subjects: 301
Study 29193547 — intervention group
Group type: EXPERIMENTAL
Intervention: telbivudine 600 mg/day from gestation 28-32 weeks to 3-4 weeks postpartum
Number of subjects: 328
Study 29193547 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiviral agent)
Number of subjects: 328
Study 29193741 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS)
Number of subjects: 17
Study 29193741 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-wheat foods
Number of subjects: 17
Study 29193757 — intervention group
Group type: EXPERIMENTAL
Intervention: C + vitamin E + selenium (C + A)
Number of subjects: 60
Study 29193757 — intervention group
Group type: EXPERIMENTAL
Intervention: C + sunflower oil (C + O)
Number of subjects: 60
Study 29193757 — intervention group
Group type: COMPARATOR
Intervention: Control diet (C)
Number of subjects: 60
Study 29193757 — intervention group
Group type: EXPERIMENTAL
Intervention: C + sunflower oil + vitamin E + selenium (A + O)
Number of subjects: 60
Study 29194206 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry (SLP) temporal-inferior RNFL
Number of subjects: 207
Study 29194206 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral-domain Optical Coherence Tomography (SD-OCT) temporal-inferior RNFL
Number of subjects: 207
Study 29194206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve fiber indicator from SLP
Number of subjects: 207
Study 29194206 — intervention group
Group type: EXPERIMENTAL
Intervention: SD-OCT mean
Number of subjects: 207
Study 29194206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GDx-VCC and SD-OCT
Number of subjects: 207
Study 29194206 — intervention group
Group type: COMPARATOR
Intervention: PPV comparison between SLP and SD-OCT
Number of subjects: 207
Study 29194206 — intervention group
Group type: COMPARATOR
Intervention: NPV comparison between SLP and SD-OCT
Number of subjects: 207
Study 29194623 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation plus perioperative SOX chemotherapy
Number of subjects: 40
Study 29194665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FIBRYGA, Octapharma AG)
Number of subjects: 13
Study 29195494 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives-based workplace wellness program
Number of subjects: 292
Study 29195593 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (BI)
Number of subjects: 359
Study 29195593 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person brief intervention (BI)
Number of subjects: 359
Study 29195764 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer decision support system (CDSS) for suicidality screening
Number of subjects: 2134
Study 29195764 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS for suicidality screening
Number of subjects: 2134
Study 29196279 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based self-management intervention
Number of subjects: 46
Study 29196279 — intervention group
Group type: EXPERIMENTAL
Intervention: paper-based self-management intervention
Number of subjects: 46
Study 29196279 — intervention group
Group type: COMPARATOR
Intervention: contact-control intervention
Number of subjects: 46
Study 29196412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV at 40 µg/kg
Number of subjects: 131
Study 29196412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV at 5-60 µg/kg or 20 µg/kg on days 1 and 4 of 21-day cycles
Number of subjects: 131
Study 29196412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV
Number of subjects: 131
Study 29196412 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadastuximab talirine IV in patients achieving CR or CRi
Number of subjects: 131
Study 29196482 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased exercise level between 15 and 20 weeks' gestation
Number of subjects: 1200
Study 29196482 — intervention group
Group type: COMPARATOR
Intervention: No change in exercise level up to 20 weeks' gestation
Number of subjects: 1200
Study 29196542 — intervention group
Group type: EXPERIMENTAL
Intervention: cMyC concentration in patients with aortic stenosis
Number of subjects: 161
Study 29197216 — intervention group
Group type: EXPERIMENTAL
Intervention: C9+ individuals
Number of subjects: 80
Study 29197216 — intervention group
Group type: EXPERIMENTAL
Intervention: C9+ individuals (younger than 40 years)
Number of subjects: 80
Study 29197216 — intervention group
Group type: COMPARATOR
Intervention: C9- individuals
Number of subjects: 80
Study 29197547 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 μg of aerosolized albuterol sulfate administered with a metered dose inhaler with space chamber
Number of subjects: 25
Study 29197984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent marijuana users
Number of subjects: 37
Study 29197984 — intervention group
Group type: COMPARATOR
Intervention: Matched non-using controls
Number of subjects: 37
Study 29198079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin and naproxen sodium
Number of subjects: 0
Study 29198079 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-dose aspirin only)
Number of subjects: 0
Study 29198186 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid risk screening tool implementation at trauma centers
Number of subjects: 0
Study 29198186 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures of socio-demographics, substance use history, opioid misuse risk, mental health, medical history, and injury and pain severity
Number of subjects: 0
Study 29198186 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward stepwise regression analysis
Number of subjects: 0
Study 29198545 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HR-QoL) questionnaire
Number of subjects: 656
Study 29198545 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity score for health conditions
Number of subjects: 656
Study 29198845 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening both during childhood and recently
Number of subjects: 1121
Study 29198845 — intervention group
Group type: COMPARATOR
Intervention: Gardening frequency (monthly or weekly)
Number of subjects: 1121
Study 29199321 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-001 3 µg + QS-21
Number of subjects: 126
Study 29199321 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-001 10 µg + QS-21
Number of subjects: 126
Study 29199321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 29199322 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3293
Number of subjects: 184
Study 29199322 — intervention group
Group type: COMPARATOR
Intervention: AZD3839
Number of subjects: 184
Study 29199322 — intervention group
Group type: COMPARATOR
Intervention: AZ1340
Number of subjects: 184
Study 29200184 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 51
Study 29200184 — intervention group
Group type: COMPARATOR
Intervention: Healthy control children
Number of subjects: 51
Study 29200971 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS13 and vWF/ADAMTS13 ratio
Number of subjects: 258
Study 29200971 — intervention group
Group type: COMPARATOR
Intervention: Aspirin treatment
Number of subjects: 258
Study 29201153 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor glycaemic control (HbA1c levels not specified)
Number of subjects: 64
Study 29201153 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (details not specified)
Number of subjects: 64
Study 29201377 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable devices (wrist-worn personal fitness tracker)
Number of subjects: 50
Study 29201388 — intervention group
Group type: EXPERIMENTAL
Intervention: PtDA intervention
Number of subjects: 82
Study 29201388 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study 29201402 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct implant knowledge
Number of subjects: 634
Study 29201402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent to use implant
Number of subjects: 634
Study 29201430 — intervention group
Group type: EXPERIMENTAL
Intervention: On-campus same-day contraceptive clinic for long-acting reversible contraception (LARC)
Number of subjects: 0
Study 29201430 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey
Number of subjects: 0
Study 29201490 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical EBRT
Number of subjects: 16
Study 29201994 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing cognitive training
Number of subjects: 2802
Study 29201994 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 2802
Study 29202623 — intervention group
Group type: EXPERIMENTAL
Intervention: ANX005, administered intravenously once weekly for 4 weeks
Number of subjects: 0
Study 29202623 — intervention group
Group type: EXPERIMENTAL
Intervention: First-in-human starting dose of ANX005
Number of subjects: 0
Study 29202720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-precision radiotherapy with 5×5 Gy in 1 week
Number of subjects: 44
Study 29202720 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy with 5×4 Gy in 1 week
Number of subjects: 44
Study 29202727 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day Holter monitoring
Number of subjects: 1511
Study 29202744 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase (MMP)-generated fragments of collagen type I (C1M) and type VI (C6M) assessed in month six serum samples.
Number of subjects: 1000
Study 29202780 — intervention group
Group type: COMPARATOR
Intervention: TGF-β isoforms (TGF-β1, TGF-β2, TGF-β3)
Number of subjects: 120
Study 29202780 — intervention group
Group type: COMPARATOR
Intervention: TGF-β3
Number of subjects: 120
Study 29202839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord tissue
Number of subjects: 295
Study 29202839 — intervention group
Group type: COMPARATOR
Intervention: Cord blood
Number of subjects: 295
Study 29202957 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental recommendation to bank sperm
Number of subjects: 122
Study 29202957 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy to facilitate banking
Number of subjects: 122
Study 29203493 — intervention group
Group type: EXPERIMENTAL
Intervention: Trough concentrations of >15 mg/liter
Number of subjects: 252
Study 29203493 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC-guided dosing with BestDose Bayesian software
Number of subjects: 252
Study 29203498 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening using serial measurements of high-sensitivity cardiac troponin T
Number of subjects: 2018
Study 29203498 — intervention group
Group type: COMPARATOR
Intervention: Patients without PMI
Number of subjects: 2018
Study 29203498 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PMI not fulfilling additional criteria for spontaneous acute myocardial infarction
Number of subjects: 2018
Study 29203585 — intervention group
Group type: EXPERIMENTAL
Intervention: selinexor (3-60 mg/m2)
Number of subjects: 25
Study 29203590 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL15 (rhIL15)
Number of subjects: 0
Study 29204372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) breakfast and afternoon snack
Number of subjects: 11
Study 29204372 — intervention group
Group type: COMPARATOR
Intervention: High glycemic index (GI) intervention
Number of subjects: 11
Study 29204958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol disoxate gel
Number of subjects: 58
Study 29205492 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus eluting stents (PF-SES)
Number of subjects: 2672
Study 29205690 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (ICM) for 20 months monitoring
Number of subjects: 105
Study 29205690 — intervention group
Group type: EXPERIMENTAL
Intervention: Software based analysis of continuously monitored electrocardiogram (SRA) during hospitalization
Number of subjects: 105
Study 29205690 — intervention group
Group type: COMPARATOR
Intervention: SRA compared to ICM
Number of subjects: 105
Study 29205690 — intervention group
Group type: EXPERIMENTAL
Intervention: ICM detection of AF
Number of subjects: 105
Study 29205690 — intervention group
Group type: COMPARATOR
Intervention: SRA prediction of AF
Number of subjects: 105
Study 29206049 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable wafers impregnated with carmustine (BCNU)
Number of subjects: 500
Study 29206476 — intervention group
Group type: EXPERIMENTAL
Intervention: Coulter blood counts and proportions
Number of subjects: 6299
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Any VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Night sweats only
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Night sweats and hot flashes
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot flashes only
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Late VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and late VMS
Number of subjects: 150007
Study 29206771 — intervention group
Group type: EXPERIMENTAL
Intervention: Early VMS
Number of subjects: 150007
Study 29206944 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (9.6 nmol/kg, one injection)
Number of subjects: 48
Study 29206944 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54 (9.6 nmol/kg, two injections at 10 h interval)
Number of subjects: 48
Study 29206944 — intervention group
Group type: EXPERIMENTAL
Intervention: Kisspeptin-54
Number of subjects: 48
Study 29206944 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 48
Study 29206944 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 48
Study 29207608 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) dose adjustment following therapeutic drug monitoring
Number of subjects: 0
Study 29207608 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided BU dose adjustments
Number of subjects: 0
Study 29207962 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month exercise program including ≥2.5 hours of intense physical activity/week, 30 minutes of strength building, and 2 hours of aerobic exercises.
Number of subjects: 150
Study 29207962 — intervention group
Group type: COMPARATOR
Intervention: Control group asked to keep physical activity levels constant.
Number of subjects: 150
Study 29207966 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-based cervical cancer screening in community health campaigns
Number of subjects: 18
Study 29207966 — intervention group
Group type: COMPARATOR
Intervention: HPV-based cervical cancer screening in health facilities
Number of subjects: 18
Study 29207976 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image discrepancy assessment among girls who chose a smaller ideal body figure than their current/actual figure (67.5%; n=1023)
Number of subjects: 1519
Study 29207976 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight status assessment
Number of subjects: 1519
Study 29207983 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led health coaching with EHR-based interventions
Number of subjects: 16
Study 29207983 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based interventions (hypertension-specific registry reports, alerts, and order sets)
Number of subjects: 16
Study 29208007 — intervention group
Group type: EXPERIMENTAL
Intervention: One session of physical therapy
Number of subjects: 14
Study 29209023 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI system with online scaling feature
Number of subjects: 2
Study 29209023 — intervention group
Group type: COMPARATOR
Intervention: Standard BCI control without online scaling feature
Number of subjects: 2
Study 29209104 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 92
Study 29209104 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6R antagonist therapy
Number of subjects: 92
Study 29209104 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD4CD69 ratio < 2.43
Number of subjects: 92
Study 29209458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal almond group (PM) - 56 g of almonds consumed before meals
Number of subjects: 169
Study 29209458 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack almond group (SN) - 56 g of almonds consumed as a snack between meals
Number of subjects: 169
Study 29209458 — intervention group
Group type: COMPARATOR
Intervention: Control group (CL) - high-carbohydrate iso-caloric control food
Number of subjects: 169
Study 29209510 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone infusion
Number of subjects: 66
Study 29209513 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 40
Study 29209513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sidestream darkfield microscopy (SDF)
Number of subjects: 40
Study 29209513 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging (LSCI)
Number of subjects: 40
Study 29209513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI)
Number of subjects: 40
Study 29209513 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus of ephedrine
Number of subjects: 40
Study 29209515 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet
Number of subjects: 12
Study 29209515 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium chain triglyceride ketogenic diet
Number of subjects: 12
Study 29209515 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ketogenic diets
Number of subjects: 12
Study 29209525 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily; 3 week continuous treatment cycles)
Number of subjects: 1066
Study 29209636 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFNB-1a)
Number of subjects: 85
Study 29209636 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NF-L
Number of subjects: 85
Study 29209946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks via pen
Number of subjects: 217
Study 29209946 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks via pen
Number of subjects: 217
Study 29209946 — intervention group
Group type: COMPARATOR
Intervention: Sarilumab 150 mg every 2 weeks via syringe
Number of subjects: 217
Study 29209946 — intervention group
Group type: COMPARATOR
Intervention: Sarilumab 200 mg every 2 weeks via syringe
Number of subjects: 217
Study 29209946 — intervention group
Group type: COMPARATOR
Intervention: Sarilumab pen and syringe groups
Number of subjects: 217
Study 29210056 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based precision medicine test (ASGES)
Number of subjects: 176
Study 29210056 — intervention group
Group type: EXPERIMENTAL
Intervention: High ASGES group
Number of subjects: 176
Study 29210056 — intervention group
Group type: COMPARATOR
Intervention: Low ASGES group
Number of subjects: 176
Study 29210351 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria treatment during pregnancy, specific intervention details not provided.
Number of subjects: 0
Study 29210443 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-001 3 µg + QS-21 adjuvant (50 µg)
Number of subjects: 63
Study 29210443 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-001 10 µg + QS-21 adjuvant (50 µg)
Number of subjects: 63
Study 29210443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 29210443 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Number of subjects: 63
Study 29210791 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase I
Number of subjects: 127
Study 29210791 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of propofol and remifentanil infusions using WAVCNS feedback in phase II
Number of subjects: 127
Study 29210791 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of remifentanil in phase II
Number of subjects: 127
Study 29210791 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of remifentanil in phase I
Number of subjects: 127
Study 29211516 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial discrimination
Number of subjects: 198
Study 29211516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low household education
Number of subjects: 198
Study 29211516 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial discrimination (girls only)
Number of subjects: 198
Study 29211516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low household education (girls only)
Number of subjects: 198
Study 29211618 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy
Number of subjects: 535